Results 11 to 20 of about 231,458 (256)
Immuno-biosensor for Detection of CD20-Positive Cells Using Surface Plasmon Resonance [PDF]
Advanced Pharmaceutical Bulletin, 2017 Purpose: Surface plasmon resonance (SPR) sensing confers a real-time assessment of molecular interactions between biomolecules and their ligands. This approach is highly sensitive and reproducible and could be employed to confirm the successful binding ...
Dariush Shanehbandi +6 more
doaj +3 more sources
Neurology International, 2022 Anti-CD20 therapies decrease the humoral response to SARS-CoV-2 immunization. We aimed to determine the extent of the humoral response to SARS-CoV-2 antigens in correlation with peripheral B-cell dynamics among patients with central nervous system ...
Julia Feige +11 more
doaj +2 more sources
Monoclonal Antibodies: from Development to Clinical Application
Клиническая онкогематология, 2016 The development of monoclonal antibodies (MABs) resulted in revolutionary achievements in diagnosing and treating of oncohematological disorders. The review dwells on the history of the development and improved technologies for production of monoclonal ...
Yurii Ivanovich Budchanov
doaj +2 more sources
Journal for ImmunoTherapy of CancerBackground A bidirectional promoter-driven chimeric antigen receptor (CAR) cassette provides the simultaneous expression of two CARs, which significantly enhances dual antigen-targeted CAR T-cell therapy.Methods We developed a second-generation CAR ...
Supannikar Tawinwung +6 more
doaj +2 more sources
Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature [PDF]
Diagnostics, 2020 Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is the most common entity of mature T-cell neoplasms. PTCL-NOS generally has an aggressive behavior and is often refractory to standard therapy.
Alessandro Mangogna +5 more
doaj +2 more sources
Treatment strategies for rituximab-resistant primary membranous nephropathy: from resistance mechanisms to emerging therapies [PDF]
Frontiers in ImmunologyWith the expanding identification of target antigens in primary membranous nephropathy (PMN), treatment is shifting from empirical immunosuppression toward mechanism-based precision immunotherapy.
Jingjie Gao +9 more
doaj +2 more sources
Selection of an Anti-CD20, Single-Chain Antibody by Phage ELISA on Fixed Cells
BioTechniques, 1999 Cloning the correct genes that code for antibody-variable domains from hybridomas is often complicated by the presence of several immunoglobulin transcripts, some of them arising from a myeloma cell line.
Stefanie Schmidt +3 more
doaj +2 more sources
CD20 positivity in classical Hodgkin′s lymphoma: Diagnostic challenge or targeting opportunity
Indian Journal of Pathology and Microbiology, 2009 Background: It is now well established that Hodgkin cells are clonal B cells with a CD30 and CD15 phenotype. However, on immunohistochemistry, in our experience and the experience of others, CD20 positivity in an otherwise typical classical Hodgkin ...
Barakzai Muhammad, Pervez Shahid
doaj +1 more source
Frontiers in Immunology, 2023 The activating receptor natural killer group 2, member D (NKG2D) represents an attractive target for immunotherapy as it exerts a crucial role in cancer immunosurveillance by regulating the activity of cytotoxic lymphocytes.
Sebastian Lutz +19 more
doaj +1 more source
Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases [PDF]
Archive of Oncology, 2009 Out of numerous studied monoclonal antibodies, only a few reached the stage of clinical application. The CD20 molecule, non-glycolysed phospholipoprotein (usually termed B1), belonging to the tetraspan (TM4SF) family, 35-37 kD, is characteristic for all ...
Pejčić Ivica, Vrbić Svetislav
doaj +1 more source